Plus Therapeutics (PSTV) Shares Outstanding (Diluted Average) (2010 - 2026)

Plus Therapeutics (PSTV) has 12 years of Shares Outstanding (Diluted Average) data on file, last reported at $6.6 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $6.6 million, up 1040.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.6 million (up 1040.62% YoY), and the FY2025 annual result was $77.8 million, up 910.35% from the prior year.
• Shares Outstanding (Diluted Average) slipped to $6.6 million in Q1 2026 per PSTV's latest filing, from $77.8 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $209.2 million in Q2 2025 and troughed at $582668.0 in Q1 2025.
• A 5-year average of $27.4 million and a median of $4.3 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Diluted Average) plunged 89.21% in 2023, then surged 2676.73% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $1.8 million in 2022, then surged by 79.45% to $3.1 million in 2023, then soared by 145.18% to $7.7 million in 2024, then soared by 910.35% to $77.8 million in 2025, then slumped by 91.46% to $6.6 million in 2026.
• Business Quant data shows PSTV's Shares Outstanding (Diluted Average) at $6.6 million in Q1 2026, $77.8 million in Q4 2025, and $107.4 million in Q3 2025.